Tests sacituzumab tirumotecan with pembrolizumab in endometrial cancer
Tests sacituzumab tirumotecan plus pembrolizumab in adults with advanced endometrial cancer.
Plain-language title generated from the registry record
Registry title: A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Key facts
- Where
- Albuquerque, Anchorage, Bethlehem, Boston, Centerville, Chattanooga, Chicago, Cincinnati, Columbus, Covington, Durham, Eugene, Fairfax, Fort Myers, Fort Wayne, Fort Worth, Gainesville, Houston, Irvine, Jackson, Kettering, Miami Beach, Mineola, Minneapolis, Mobile, New Haven, New York, Oklahoma City, Orange, Orlando, Philadelphia, Pinehurst, Pittsburgh, Providence, Reno, Richmond, San Antonio, Savannah, Scarborough, Shreveport, Solvang, St Louis, St. Petersburg, Teaneck, Tulsa, Tyler, Walnut Creek, Washington D.C., Webster, and West Palm Beach, United StatesSee the 53 sites
- Phase
- Phase 3
Where in United States
- University of New Mexico Comprehensive Cancer Center (Site 6046)Albuquerque, United StatesTaking people
- Alaska Women's Cancer Care (Site 6036)Anchorage, United StatesTaking people
- St. Luke's University Health Network (Site 6041)Bethlehem, United StatesTaking people
- Tufts Medical Center (Site 6052)Boston, United StatesTaking people
- Miami Valley Hospital South (Site 6014)Centerville, United StatesTaking people
- Erlanger Medical Center (Site 5009)Chattanooga, United StatesTaking people
- University of Chicago Medical Center (Site 5002)Chicago, United StatesTaking people
- University of Cincinnati Medical Center (Site 5013)Cincinnati, United StatesTaking people
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C (Site 6007)Columbus, United StatesTaking people
- Women's Cancer Care (Site 6010)Covington, United StatesTaking people
- Duke Cancer Institute (Site 6049)Durham, United StatesTaking people
- Oncology Associates of Oregon, P.C. (Site 8005)Eugene, United StatesTaking people
- Inova Schar Cancer Institute (Site 6003)Fairfax, United StatesTaking people
- Virginia Cancer Specialists (VCS) (Site 8008)Fairfax, United StatesTaking people
- Florida Cancer Specialists - South (Site 7003)Fort Myers, United StatesTaking people
- Parkview Research Center (Site 6008)Fort Wayne, United StatesTaking people
- Texas Oncology - DFW (Site 8004)Fort Worth, United StatesTaking people
- UF Health Davis Cancer Pavilion and Shands Med Plaza (Site 6026)Gainesville, United StatesTaking people
- Houston Methodist Hospital (Site 6057)Houston, United StatesTaking people
- CHAO Family Comprehensive Cancer Center and Ambulatory Care (Site 5014)Irvine, United StatesTaking people
- St. Dominic's Hospital (Site 5004)Jackson, United StatesTaking people
- Kettering Health Main Campus-Kettering Health Cancer Center (Site 5001)Kettering, United StatesTaking people
- Mount Sinai Braman Comprehensive Cancer Center (Site 6031)Miami Beach, United StatesTaking people
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island (Site 6055)Mineola, United StatesTaking people
- Minnesota Oncology Hematology, PA (Site 8003)Minneapolis, United StatesTaking people
- University of South Alabama, Mitchell Cancer Institute (Site 6033)Mobile, United StatesTaking people
- Yale University School of Medicine (Site 6009)New Haven, United StatesTaking people
- Laura and Isaac Perlmutter Cancer Center at NYU Langone (Site 6004)New York, United StatesTaking people
- Memorial Sloan Kettering Cancer Center (Site 6053)New York, United StatesTaking people
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center (Site 6012)Oklahoma City, United StatesTaking people
- University of California, Irvine (UCI) Health - UC Irvine Medical Center (Site 6020)Orange, United StatesTaking people
- AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology (Site 6002)Orlando, United StatesTaking people
- Hospital of the University of Pennsylvania (Site 5007)Philadelphia, United StatesTaking people
- Hospital of the University of Pennsylvania (Site 6023)Philadelphia, United StatesNo longer taking part
- FirstHealth of the Carolinas (Site 6037)Pinehurst, United StatesTaking people
- AHN West Penn Hospital (Site 6006)Pittsburgh, United StatesTaking people
- Women & Infants Hospital (Site 5003)Providence, United StatesTaking people
- The Center of Hope (Site 5018)Reno, United StatesTaking people
- VCU Health Adult Outpatient Pavillion (Site 5000)Richmond, United StatesTaking people
- Texas Oncology-San Antonio Medical Center (Site 8001)San Antonio, United StatesTaking people
- St. Joseph's/Candler Health System (Site 6021)Savannah, United StatesTaking people
- Maine Medical Center - Scarborough Campus (Site 6042)Scarborough, United StatesTaking people
- TRIALS 365 (Site 6005)Shreveport, United StatesTaking people
- Sansum Clinic (Ridley Tree) (Site 8007)Solvang, United StatesTaking people
- Washington University - School of Medicine (Site 5006)St Louis, United StatesTaking people
- Florida Cancer Specialists (Site 7002)St. Petersburg, United StatesTaking people
- Holy Name Medical Center (Site 6011)Teaneck, United StatesTaking people
- Oklahoma Cancer Specialists and Research Institute, LLC (Site 6047)Tulsa, United StatesTaking people
- Texas Oncology - Northeast Texas (Site 8002)Tyler, United StatesTaking people
- John Muir Health Cancer Center (Site 6028)Walnut Creek, United StatesTaking people
- MedStar Washington Hospital Center (Site 5005)Washington D.C., United StatesTaking people
- Texas Oncology - Gulf Coast (Site 8006)Webster, United StatesTaking people
- Florida Cancer Specialists East (Site 7001)West Palm Beach, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- NCT06952504EU 2024-519331-42-00
- Record updated
- 10 November 2026
- Original description
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.Read full original descriptionShow less
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.
* EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery
Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells.
The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.
Inclusion: Has a histologically confirmed diagnosis of primary advanced or recurrent endometrial carcinoma that has been confirmed as proficient mismatch repair (pMMR); Has radiographically evaluable disease, with measurable Stage III or either measurable or non-measurable Stage IV or recurrent disease per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), as assessed by the investigator; Has received no prior systemic therapy for endometrial carcinoma except the following conditions as pre-specified by the protocol: 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of curative-intent, prior radiation with or without radiosensitizing chemotherapy if >2 weeks before the start of induction treatment, or prior hormonal therapy for treatment of endometrial carcinoma that was discontinued ≥1 week before the start of induction treatment.
Exclusion: Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease; Received prior therapy in any setting with any of the following: anti-programmed cell death 1 protein, anti-programmed cell death ligand 1, anti-programmed cell death ligand 2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor; trophoblast cell surface antigen 2-targeted antibody drug conjugate; or topoisomerase I inhibitor-containing antibody drug conjugate; Is a candidate for debulking surgery resulting in complete removal of all tumor and no evidence of radiological disease following surgery, or curative-intent radiotherapy at the time of enrollment; Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing; Has uncontrolled, significant cardiovascular disease or cerebrovascular disease; Human Immunodeficiency Virus-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease; Has carcinosarcoma, neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of sarcomas; Has endometrial carcinoma of any histology that is mismatch repair deficient (dMMR).